Análisis económico del trastuzumab en Colombia.

id	metarevistapublica_acho_revistacolombianadehematologiayoncologia_27_article_339
record_format	ojs
spelling	Análisis económico del trastuzumab en Colombia. Economic analysis of trastuzumab in Colombia. Carranza, Hernán Vargas, Carlos Bernal, Laura Otero, Jorge Miguel Cardona, Andrés Felipe 2 2 Núm. 2 , Año 2013 : Julio Artículo de revista Journal article 2013-07-01T00:00:00Z 2013-07-01T00:00:00Z 2013-07-01 application/pdf Asociación Colombiana de Hematología y Oncología (ACHO) Revista Colombiana de Hematología y Oncología 2256-2877 2256-2915 https://revista.acho.info/index.php/acho/article/view/339 10.51643/22562915.339 https://doi.org/10.51643/22562915.339 spa https://creativecommons.org/licenses/by-nc-sa/4.0 Hernán Carranza - 2013 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. 12 14 Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, et al.; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4 Suppl 3:S1-22; quiz S23-4. Buendía JA, Vallejos C, Pichón-Rivière A. Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia. Biomédica. 2013;33(3). Comisión de Regulación en Salud. Reporte de evaluación de posible inclusión al POS para trastuzumab. Universidad Nacional de Colombia, Facultad de Medicina, Instituto de Investigaciones Clínicas. Ministerio de Salud y Protección Social, Colciencias, Centro de Estudios e Investigación en Salud de la Fundación Santa Fe de Bogotá, Escuela de Salud Pública de la Universidad de Harvard. Guía metodológica para el desarrollo de guías de atención integral. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):1-192. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409-18. Drummond MF, Sculper MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. Chicaíza L, Vega R. Determinantes de la utilización de la evaluación económica en la toma de decisiones dentro del sistema de salud colombiano. Innovar Revista de Ciencias Administrativas y Sociales, Universidad Nacional de Colombia. 2012;18(31):77-9. Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673-85. Ferrusi IL, Leighl NB, Kulin NA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? ajmc.com [online] 2011 [cited 2013 Jul 8]. Available from: http://www.ajmc.com/publications/supplement/2011/AJMC_11JOPmay/AJMC_11JOPmay_Ferrusi_SP61to70/4. NICE. Appraising life-extending, end of life treatments. 2009. Avalilable from: http://www.nice.org.uk/media/88A/F/supplementaryAdviceTACEoL.pdf. BID. Método de la costo-efectividad incremental. 2013. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold. Danese MD, Lalla D, Brammer M, Doan Q, Knopf K. Estimating recurrences prevented from using trastuzumab in HER-2/neupositive adjuvant breast cancer in the United States. Cancer. 2010;116(24):5575-83. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. NICE technology appraisal guidance 107, 2006. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Costeffectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol. 2007;18(9):1493-9. Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011;50(3):344-52. Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B, Barrett-Lee P. Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J Cancer. 2012;106(1):32-8. Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559-66. Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12 Suppl 3:S82-4. https://revista.acho.info/index.php/acho/article/download/339/301 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_b239 http://purl.org/redcol/resource_type/ARTEDIT info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication
institution	ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA
thumbnail	https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png
country_str	Colombia
collection	Revista Colombiana de Hematología y Oncología
title	Análisis económico del trastuzumab en Colombia.
spellingShingle	Análisis económico del trastuzumab en Colombia. Carranza, Hernán Vargas, Carlos Bernal, Laura Otero, Jorge Miguel Cardona, Andrés Felipe
title_short	Análisis económico del trastuzumab en Colombia.
title_full	Análisis económico del trastuzumab en Colombia.
title_fullStr	Análisis económico del trastuzumab en Colombia.
title_full_unstemmed	Análisis económico del trastuzumab en Colombia.
title_sort	análisis económico del trastuzumab en colombia.
title_eng	Economic analysis of trastuzumab in Colombia.
author	Carranza, Hernán Vargas, Carlos Bernal, Laura Otero, Jorge Miguel Cardona, Andrés Felipe
author_facet	Carranza, Hernán Vargas, Carlos Bernal, Laura Otero, Jorge Miguel Cardona, Andrés Felipe
citationvolume	2
citationissue	2
citationedition	Núm. 2 , Año 2013 : Julio
publisher	Asociación Colombiana de Hematología y Oncología (ACHO)
ispartofjournal	Revista Colombiana de Hematología y Oncología
source	https://revista.acho.info/index.php/acho/article/view/339
language	spa
format	Article
rights	https://creativecommons.org/licenses/by-nc-sa/4.0 Hernán Carranza - 2013 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
references	Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, et al.; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4 Suppl 3:S1-22; quiz S23-4. Buendía JA, Vallejos C, Pichón-Rivière A. Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia. Biomédica. 2013;33(3). Comisión de Regulación en Salud. Reporte de evaluación de posible inclusión al POS para trastuzumab. Universidad Nacional de Colombia, Facultad de Medicina, Instituto de Investigaciones Clínicas. Ministerio de Salud y Protección Social, Colciencias, Centro de Estudios e Investigación en Salud de la Fundación Santa Fe de Bogotá, Escuela de Salud Pública de la Universidad de Harvard. Guía metodológica para el desarrollo de guías de atención integral. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):1-192. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409-18. Drummond MF, Sculper MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. Chicaíza L, Vega R. Determinantes de la utilización de la evaluación económica en la toma de decisiones dentro del sistema de salud colombiano. Innovar Revista de Ciencias Administrativas y Sociales, Universidad Nacional de Colombia. 2012;18(31):77-9. Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673-85. Ferrusi IL, Leighl NB, Kulin NA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? ajmc.com [online] 2011 [cited 2013 Jul 8]. Available from: http://www.ajmc.com/publications/supplement/2011/AJMC_11JOPmay/AJMC_11JOPmay_Ferrusi_SP61to70/4. NICE. Appraising life-extending, end of life treatments. 2009. Avalilable from: http://www.nice.org.uk/media/88A/F/supplementaryAdviceTACEoL.pdf. BID. Método de la costo-efectividad incremental. 2013. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold. Danese MD, Lalla D, Brammer M, Doan Q, Knopf K. Estimating recurrences prevented from using trastuzumab in HER-2/neupositive adjuvant breast cancer in the United States. Cancer. 2010;116(24):5575-83. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. NICE technology appraisal guidance 107, 2006. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Costeffectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol. 2007;18(9):1493-9. Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011;50(3):344-52. Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B, Barrett-Lee P. Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J Cancer. 2012;106(1):32-8. Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559-66. Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12 Suppl 3:S82-4.
type_driver	info:eu-repo/semantics/article
type_coar	http://purl.org/coar/resource_type/c_6501
type_version	info:eu-repo/semantics/publishedVersion
type_coarversion	http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content	Text
publishDate	2013-07-01
date_accessioned	2013-07-01T00:00:00Z
date_available	2013-07-01T00:00:00Z
url	https://revista.acho.info/index.php/acho/article/view/339
url_doi	https://doi.org/10.51643/22562915.339
issn	2256-2877
eissn	2256-2915
doi	10.51643/22562915.339
citationstartpage	12
citationendpage	14
url2_str_mv	https://revista.acho.info/index.php/acho/article/download/339/301
_version_	1811200923575255040

Análisis económico del trastuzumab en Colombia. .

Código QR

Estadísticas y Métricas Alternativas

Títulos similares

Análisis económico del trastuzumab en Colombia.
.